Holen Sie sich die Stockscreener-App
8.54
1.55%
0.13
Handel nachbörslich:
8.60
0.06
+0.70%
Schlusskurs vom Vortag:
$8.41
Offen:
$8.2
24-Stunden-Volumen:
3.21M
Relative Volume:
2.18
Marktkapitalisierung:
$705.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-314.85M
KGV:
-2.3838
EPS:
-3.5825
Netto-Cashflow:
$-283.27M
1W Leistung:
+18.61%
1M Leistung:
+5.82%
6M Leistung:
+82.48%
1J Leistung:
+14.48%
1-Tages-Spanne:
$8.20
$8.85
1-Wochen-Bereich:
$7.25
$8.85
52-Wochen-Spanne:
$2.68
$13.24
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.54 | 694.44M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
Replimune Shares Face Pivotal FDA Decision on RP1 Therapy - AD HOC NEWS
Replimune Group Inc. Faces Mixed Market Reactions Amid Financial Updates - timothysykes.com
Replimune Sees Positive Momentum Amid Strategic Developments - StocksToTrade
Replimune Group Inc. Stock Dips Amid Financial Challenges and Market Pressures - timothysykes.com
Replimune Stock Soars Amidst Strategic Developments and Financial Innovation - StocksToTrade
Replimune’s Positive Market Trends Amid Key Financial Developments - StocksToTrade
REPL PE Ratio & Valuation, Is REPL Overvalued - Intellectia AI
Replimune, Grace among biotechs with April PDUFA dates - biocentury.com
REPL files Form 144 notice (NASDAQ: REPL) with RSU vesting details - Stock Titan
Replimune Group Inc (7R8.SG) stock price, news, quote and history - Yahoo Finance Singapore
Replimune Group (NASDAQ:REPL) Shares Up 7.2%Should You Buy? - MarketBeat
Replimune Shares Approach a Pivotal Regulatory Verdict - AD HOC NEWS
Meme Stocks: Can Replimune Group Inc expand its profit margins2026 Snapshot & AI Driven Price Predictions - baoquankhu1.vn
Entry Recap: Is Replimune Group Inc stock undervalued right now2026 Price Targets & Verified Swing Trading Watchlists - baoquankhu1.vn
Replimune Group (FRA:7R8) PB Ratio : 2.79 (As of Mar. 28, 2026) - GuruFocus
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Wall Street analysts predict a 65.72% upside in Replimune Group (REPL): Here's what you should know - MSN
Aug Update: Is now the right time to enter Replimune Group Inc2026 Price Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Analyst Upgrade: Is IBTA affected by consumer sentiment2026 Performance Recap & Capital Efficiency Focused Ideas - baoquankhu1.vn
REPL Technical Analysis | Trend, Signals & Chart Patterns | REPLIMUNE GROUP INC (NASDAQ:REPL) - chartmill.com
Replimune's Oncolytic Viral Therapy For Melanoma Faces Second Shot At FDA Approval - RTTNews
Replimune Shares Skyrocket After FDA Accepts Resubmitted BLA for Melanoma Therapy - MSN
Aug PostEarnings: Does Replimune Group Inc align with a passive investing strategyWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Does Replimune Group (REPL) have the potential to rally 79.61% as Wall Street analysts expect? - MSN
Fcpm Iii Services B.V. Boosts Position in Replimune Group, Inc. $REPL - MarketBeat
Institutional Investors Double Down on Replimune Amid Market Turmoil () - aktiencheck.de
Boxer Capital Management LLC Has $4.40 Million Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat
Braidwell LP Boosts Stock Holdings in Replimune Group, Inc. $REPL - MarketBeat
Quinn Opportunity Partners LLC Invests $2.73 Million in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group (NASDAQ:REPL) Stock Price Down 8%Here's What Happened - MarketBeat
Wedbush Upgrades Replimune Group (REPL) - MSN
REPL: Awaiting April 10th PDUFA for RP1, with commercial launch readiness and robust pipeline progress - TradingView
Replimune Group (NASDAQ:REPL) Trading 11.1% HigherHere's Why - MarketBeat
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - Finviz
Replimune Stock Quote, Share Price, News and Analysis - Longbridge
REPL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Does Replimune Group (REPL) Possess the Opportunity to Surge by 79.61% According to Wall Street Analysts' Predictions? - Bitget
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect? - Finviz
Replimune to Present at Two Upcoming Investor Conferences - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Hold" by Analysts - MarketBeat
Erste Asset Management GmbH Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat
Replimune Group, Inc. (REPL) Stock Analysis: A High-Potential Biotech Play with 67% Upside - DirectorsTalk Interviews
Replimune Group Stock Price Forecast. Should You Buy REPL? - StockInvest.us
Replimune's Pivotal FDA Verdict Approaches - AD HOC NEWS
Market Leaders: Can Replimune Group Inc expand its profit margins2025 Fundamental Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Analyst Calls: Is Apyx Medical Corporation in accumulation or distribution phaseEarnings Miss & Real-Time Volume Analysis - baoquankhu1.vn
Replimune Shares Approach a Pivotal Regulatory Milestone - AD HOC NEWS
Replimune Group, Inc. (REPL) Stock Analysis: Unpacking a 50% Potential Upside in Biotechnology - DirectorsTalk Interviews
Replimune: Multiple Shots On Goal But A High Risk Binary Approaches - Seeking Alpha
What is Replimune Group Inc.’s market positionQuarterly Profit Summary & Precise Swing Trade Entry Alerts - mfd.ru
Replimune Group (REPL) director gifts 25,000 common shares - Stock Titan
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dhingra Kapil | Director |
Dec 09 '25 |
Option Exercise |
1.75 |
3,169 |
5,546 |
3,169 |
| Dhingra Kapil | Director |
Dec 09 '25 |
Sale |
10.40 |
3,169 |
32,958 |
0 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):